The role of electron-emitting radiopharmaceuticals in the palliative treatment of metastatic bone pain and for radiosynovectomy: Applications of conversion electron emitter tin-117m

Brazilian Archives of Biology and Technology

Volumn 50, Issue SPECIALISSUE, 2007, Pages 49-62

  Srivastava, Suresh C ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

Bone pain palliation; Conversion electron emitters; Radionuclide therapy; Radiosynovectomy; Tin 117m

Indexed keywords

EID: 80053192896     PISSN: 15168913     EISSN: 16784324     Source Type: Journal    
DOI: 10.1590/S1516-89132007000600007     Document Type: Article

References (54)

1. Aldestein, S. J., Manning, F. J. (1995), Isotopes for Medicine and the Life Sciences. Washington, D.C., National Academy Press.
2. Atkins, H. L., Mausner, L. F., Srivastava, S. C., Meinken, G. E., Cabahug, C. J., Straub, R. F., Cabahug, C. J., Weber, D. A., Wong, C. T., Sacker, D. F., Madjewicz, S. (1993), Biodistribution of Sn- 117m(4+) DTPA: A new agent for palliative treatment of painful osseous metastases. Radiology, 186, 279-283.
3. Atkins, H. L., Mausner, L. F., Srivastava, S. C., Meinken, G. E., Cabahug, C. J., D'Alessandro, T. (1995), Tin-117m(4+)DTPA for palliation of pain from osseous metastases: A pilot study. J. Nucl. Med., 36, 725-729.
4. Barrenechea, E., Amaral, H. (2003), From Gold to Tin: A new coordinated research project on "Comparative evaluation of the efficacy of radiosynovectomy with conventional intra-articular therapy in rheumatoid arthritis and hemophilic arthropathy (CERAHA). World J. Nucl. Med., 2, 155-156.
5. Bishayee, A., Rao, D. V., Srivastava, S. C., Bouchet, L. G., Bolch, W. E., Howell, R. W. (2000), Marrow Sparing Effects of Sn-117m (4+) DTPA for radionuclide therapy of bone cancer. J. Nucl. Med., 41, 2043-2050.
6. Boussina, I., Toussaint, M., Ott, H. (1979), A double blind study of Er-169 synoviorthesis in rheumatoid digital joints. Scand. J. Rheumatology, X8, 71-74.
7. Chinol, M. Vallabhajousula, S., Goldsmith, S. (1993), Chemistry and Biological Behavior of Samarium-153 and Rhenium-186- labeled Hydroxyapatite Particles: Potential Radiopharmaceutical for Radiation Synovectomy. J. Nucl. Med., 34, 1536.
8. Collins, C., Eary, J. F., Donaldson, G., Vernon, C., Bush, N. E., Petersdorf, S., Livingston, R. B., Gordon, E. E., Chapman, C. R., Appelbaum, F. R. (1993), Samarium-153-EDTMP in bone metastases of hormone refractory prostate cancer: a phase I/II trial. J. Nucl. Med., 34, 1839-1844.
9. de Klerk, J. M. H., van Dijk, A., van het Schip, A. D., Zonnenberg, B. A., van Rijk, P. P., (1992), Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J. Nucl. Med., 33, 646-651.
10. Deutsch, E., Broadack, J., Deutsch, K. (1993), Radiation Synovectomy Revisited. Eur. J. Nucl. Med., 20, 1113 [and references therein].
11. EANM (2003), Procedure Guidelines for Radiosynovectomy. Eur. J. Nucl. Med., 30, BP12 - BP16.
12. Ercan, M. T., Caglar, M. (2000), Therapeutic radiopharmaceuticals. Cur. Pharm. Design, 6, 1085- 1121.
13. Ermolaev, S. V., Zhuikov, B. L., Kokhanyuk, V. M., Srivastava, S. C. (2006), Production yields of tin- 117m from natural antimony target in proton energy range 145 - 35 MeV. Presented at the 9th International Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, Edinburgh, U.K.
14. Farhangi, M., Holmes, R. A., Volkert, W. A., Logan, W., Singh, A. (1992), Samarium-153 EDTMP: Pharmacokinetics, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J. Nucl. Med., 33, 1451-1458.
15. Fettich, J., Padhy, A., Nair, N., Morales, R., Tamumihardja, M., Riccabonna, G., Nair, G. (2003), Comparative clinical efficacy and safety of phosphorus-32 and strontium-89 in the palliative treatment of metastatic bone pain: Results of an IAEA Coordinated Research Project. World J. Nucl. Med., 2, 226-231.
16. Firusian, N., Mellin, P., Schmidt, C. (1976), Results of 89Sr therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J. Urology, 16, 764-768.
17. 89Strontium in bone metastases from hormone resistant prostate cancer: Palliation effect and biochemical changes. Brit. J. Cancer, 66, 177- 180.
18. Friedell, H. L. and Storaasli, J. P. (1950), The use of radioactive phosphorus in the treatment of carcinoma of bthe breast with widespread metastases to bone. Am. J. Roentgenol., 64, 559-575.
19. Humm, J. L. (1986), Dosimetric aspects of radiolabeled antibodies for tumor therapy. J. Nucl. Med., 27, 1490-1497.
20. Katin, M. J., Salenius, S. A. and Blitzer, P. H. et al. (1993), Hematologic effects of Sr-89 treatment for metastases to bone. Proc. Amer. Soc. Clin. Oncol., 3, 12.
21. Kennedy, J. M., Marinelli, L. D., Woodard, H. Q. (1941), Tracer studies with radioactive phosphorus in malignant neoplastic disease. Radiology, 37, 683-690.
22. Krishnamurthy, G. T., Swailem, F. M., Srivastava, S. C., Atkins, H. L., Simpson, I. J., Walsh, T. K., Ahmann, F. R., Meinken, G. E., Shah, J. H. (1997), Sn-117m(4+)DTPA pharmacokinetics and imaging characteristics in patients with metastatic bone pain. J. Nucl. Med., 38, 230-237.
23. Lewington, V. J., McEwan, A. J., Ackery, D. M., Bayly, R. J., Keeling, D. H., Macleod, P. M., Porter, A. T., Zivanovic, M. A. (1991), A prospective, randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur. J. Cancer, 27, 954-958.
24. 117mSn DTPA. J. Nucl. Med., 42: 21P.
25. 188Re-HEDP in human prostate cancer skeletal metastases. J. Nucl. Med., 44, 953-960.
26. Liepe, K., Kropp, J., Hliscs, R., Franke, W. G. (2000), Significant reduction of the mass of bone metastasis one year after Rhenium-186-HEDP pain palliation therapy. Clin Nucl Med., 25, 901-904.
27. Mausner, L.F., Srivastava, S.C. (1993), Selection of radionuclides for radioimmunotherapy. Med. Phys., 20, 503-509.
28. Maxon, H. R., Schroder, L .E., Thomas, S. R., Hertzberg, V. S., Deutsch, E. A., Scher, H. I., Samaratunga, R. C., Libson, K. F., Williams, C. C., Moulton, J. S. (1990), Re-186(Sn)HEDP for treatment of painful osseous metastases: Initial clinical experience in 20 patients with hormoneresistant prostate cancer. Radiology, 176, 155-159.
29. McEwan, A. J. B. (1994), Radiopharmaceuticals for palliative treatment of painful bone metastases. New Perspec. Cancer. Diagn. Management, 1, 24-31.
30. Modder, G. (2001), Radiosdynoviorthesis: Involvement of Nuclear Medicine in Rheumatology and Orthopedics, Warlich Druck und Verlagsges, mbH Publishers.Meckenheim, Germany.
31. O'Donoghue, J. A., Bardiès, M., Wheldon, T. E. (1995), Relationships between tumor size and curability for uniformly targeted therapy with betaemitting radionuclides. J. Nucl. Med., 36, 1902-1909.
32. Oster, Z. H., Som, P., Srivastava, S. C., Fairchild, R. G., Meinken, G. E., Tillman, D. Y., Sacker, D. F., Richards, P., Atkins, H. L., Brill, A. B., et al. (1985), The development and in-vivo behavior of tin containing radiopharmaceuticals II. Autoradiographic and scintigraphic studies in normal animals and in animal models of disease. Int. J. Nucl. Med. Biol., 12, 175-184.
33. Pecher, C. (1942), Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of bone cancer. University of California Publications in Pharmacology, 11: 117-149.
34. Porter, A. T., McEwan, A. J. B., Powe, J. E., Reid, R., McGowan, D. G., Lukka, H., Sathyanarayana, J. R., Yakemchuk, V. N., Thomas, G. M., Erlich, L. E. (1993), Results of a randomized phase-II trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Physics, 25, 805-813.
35. Quilty, P. M., Kirk, D., Bolger, J. J., Dearnaley, D. P., Lewington, V. J., Mason, M. D., Reed, N. S., Russell, J. M., Yardley, J. (1994), A comparison of the palliative effects of strontium-89 and external beam therapy radiotherapy in metastatic prostate cancer. Radiother. Oncol., 31, 33-40.
36. 153Smethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur. J. Cancer, 33, 1583-1591.
37. Robinson, R. G. (1986), Radionuclides for the alleviation of bone pain in advanced malignancy. Clin. Oncol., 5, 39-49.
38. Robinson, R. G. Blake, G. M. and Preston, D. F., McEwan, A. J., Spicer, J. A., Martin, N. L., Wegst, A. V., Ackery, D. M. (1989), Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics, 9, 271-281.
39. Robinson, R. G., Spicer, J. A., Preston, D. F., Wegst, A. V., Martin, N. L. (1987), Treatment of metastatic bone pain with strontium-89. Nucl. Med. Biol., 14, 219-222.
40. Srivastava, S. C. (1996), Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother. Radiopharm., 11, 43-50.
41. Srivastava, S. C. (1996), Therapeutic Radionuclides: Making the Right Choice. in Mather, S.J. (ed): Current Directions in Radiopharmaceutical Research and Development, 1996, Dordrecht, The Netherlands, Kluwer Academic Publishers, pp 63-79.
42. Srivastava, S. C. (1996), Therapeutic Radionuclides: Making the Right Choice. In- Mather, S. J. (ed.). Current Directions in Radiopharmaceutical Research and Development. Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 63-79.
43. Srivastava S. C. (1999), Traditional and new isotopes for radioimmunotherapy. in Riva P (ed): Therapy of malignancies with radioconjugated monoclonal antibodies: Present possibilities and future perspectives, Chur, Switzerland, Harwood Academic Publishers, pp 11-26.
44. Srivastava, S. C. (2002), Bone-Seeking Therapeutic Radiopharmaceuticals. Braz Arch Biol Technol, 45, 45-56.
45. Srivastava, S. C., Atkins, H. L. and Krishnamurthy, G. T. et al., Treatment of metastatic bone pain with tin- 117m stannic DTPA: A phase I/II clinical study. Clin. Cancer Res., 1998; 4: 61-68.
46. Srivastava, S. C., Dadachova, E. (2001), Recent Advances in Radionuclide Therapy. Seminars in Nucl. Med., 31, 330-341.
47. Srivastava, S. C., Meinken, G. E., Richards, P., Som, P., Oster, Z. H., Atkins, H. L., Brill, A. B., Knapp, F. F. Jr., Butler, T. A. (1985), The development and invivo behavior of tin containing radiopharmaceuticals I. Chemistry, preparation and biodistribution in small animals. Int. J. Nucl. Med. Biol., 12, 167-174.
48. 186Re-HEDP and other agents for bone pain therapy. In- Nicolini, M. et al. (Eds.). Fourth International Symposium on Technetium in Chemistry and Nuclear Medicine. SG Editoriali, Padova, Italy, pp. 287-292.
49. Srivastava, S. C., Meinken, G. E., James, J. L. (1998), Characterization and In-vivo Testing of HPLCpurified Sn-117m Stannic DTPA Preparations. Eur. J. Nucl. Med., 25, 979.
50. Srivastava, S. C., Meinken, G. E., Li, Z. (2002), A novel synthetic method for preparing Sn-117m Stannic DTPA for therapeutic use. J. Nucl. Med., 43, 372P.
51. Toporov, Yu.G., Andreeyev, O. I., Vakhetov, F. Z., Gavrilov, V. D., Srivastava, S.C. (2006), High specific activity tin-117m reactor production at RIAR. Presented at the 9th International Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, Edinburgh, U.K.
52. Turner, J. H., Claringbold, P. G. (1991), A phase II study of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur. J. Cancer, 27, 1084-1086.
53. Volkert, W. A., Goeckler, W.F., Ehrhardt, G.J., Ketring, A. R. (1991), Therapeutic radionuclides: production and decay property considerations. J. Nucl. Med., 32,174-185.
54. Wheldon, T. E. (1994), Targeting radiation to tumors. Int. J. Radiat. Biol., 65, 109-116.